Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo

Circulation

Volumn 99, Issue 15, 1999, Pages 1997-2002

  Pierangeli, Silvia S ^a   Colden Stanfield, Margaret ^a   Liu, Xiaowei ^a   Barker, John H ^b   Anderson, Gary L ^b   Harris, E Nigel ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Antiphospholipid antibodies; Cell adhesion molecules; Endothelial cells; Thrombosis

Indexed keywords

CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; PHOSPHOLIPID ANTIBODY; PROTEIN C; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CELL ADHESION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HYPERCOAGULABILITY; MALE; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; THROMBOSIS;

EID: 0033586656     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.15.1997     Document Type: Article

References (46)

1. Harris EN. Syndrome of the black swan. Br J Rheumatol. 1987;26: 324-326.
2. Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH, Machin SJ, Barquinero J, Outt HH, Harris EN, Vilardell-Torres M, Hughes GR. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine. 1989;68:366-374.
3. Sammaritano LR, Gharavi AE, Lockshin MD. Antiphospholipid antibody syndrome: immunologic and clinical aspects. Semin Arthritis Rheum. 1990;20:81-96.
4. Pierangeli SS, Barker JH, Stikovac D, Ackerman D, Anderson G, Barquinero J, Acland R, Harris EN. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemost. 1994;17:670-674.
5. Pierangeli SS, Liu Xwei, Anderson GH, Barker JH, Harris EN. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost. 1995;74:1361-1367.
6. 2-glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. Circulation. 1996;94:1746-1751.
7. Olee T, Pierangeli SS, Handley HH, Le DT, Wei X, Lai CJ, En J, Novotny W, Harris EN, Woods V, Chen PP. A monoclonal IgG anticardiolipin antibody from a patient with the antiphospholipid syndrome is thrombogenic in mice. Proc Natl Acad Sci U S A. 1996;93:8606-8611.
8. Khamashta MA, Harris EN, Gharavi AE, Derue G, Gil A, Vazquez JJ, Hughes GRV. Immune mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis. 1988;47: 854-856.
9. Out HJ, deGroot PG, van Vliet M. Antibodies to platelet in patients with anti-phospholipid antibodies. Blood. 1991;77:2655-2659.
10. Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effect of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost. 1995;73:519-524.
11. Reverter JC, Tassies D, Font J, Monteagudo J, Escolar G, Ingelmo M, Ordinas A. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S. Arterioscler Thromb Vasc Biol. 1996;16:1319-1326.
12. Walker TS, Triplett DA, Javed N, Musgrave K. Evaluation of lupus anticoagulants: antiphospholipid antibodies, endothelium associated immunoglobulin, endothelial prostacyclin secretion, and antigen protein S levels. Thromb Res. 1988;51:267-271.
13. Rustin MHA, Bull HA, Machin SJ, Isenber DA. Effects of the lupus anticoagulant in patients with systemic lupus erythematosus on endothelial cell prostacyclin release and procoagulant activity. J Invest Dermatol. 1988;90:744-748.
14. Watson TS, Schorer AE. Lupus anticoagulant inhibition of in vitro prostacyclin release is associated with a thrombosis-prone subset of patients. Am J Med. 1991;90:47-53.
15. Vismara A, Meroni PL, Tincani A, Harris EN, Barcellini W, Brucato A. Relationship between anti-cardiolipin and endothelial cell antibodies in systemic lupus erythematosus. Clin Exp Immunol. 1988;74:247-252.
16. Hasselaar P, Derksen RHWM, Ousting JD, Blokzijl L, de Groot PG. Synergistic effect of low doses of tumor necrosis factor and sera from patients with systemic lupus erythematosus on the expansion of procoagulant activity by cultured endothelial cells. Thromb Haemost. 1989;62: 654-660.
17. Carreras LO, Vermylen JG. "Lupus" anticoagulant and thrombosis: possible role of inhibition of prostacyclin formation. Thromb Haemost. 1982;48:28-40.
18. Angeles-Cano ER, Sultan Y, Clauvel JP. Predisposing factors to thrombosis in systemic lupus erythematosus: possible relation to endothelial damage. J Lab Clin Med. 1979;94:312-323.
19. Pierangeli SS, Kozima K, Fernandez JH, Griffin JH, Harris EN. Inhibition of protein C activation by antiphospholipid antibodies in vitro is dependent on the composition of phospholipid (PL) liposomes used as template. Arthritis Rheum. 1996;39:S94.
20. Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol. 1990;76:101-107.
21. Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood. 1989;74:2426-2432.
22. Simantov E, LaSala J, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, Silverstein RL. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest. 1995;96:2211-2219.
23. 2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol. 1995;13:179-185.
24. Barker JH, Gu JM, Anderson GL, O'Shaughnessy M, Pierangeli S, Johnson P, Galletti G, and Acland RD. The effects of heparin and dietary fish oil on embolic events and the microcirculation downstream from a small artery repair. Plast Reconstr Surg. 1993;91:335-343.
25. Pemberton M, Anderson GL, Barker JH. Characterization of microvascular vasoconstriction following ischemia/reperfusion in skeletal muscle using video microscopy. Microsurgery 1996;17:9-16.
26. Harris EN. Antiphospholipid antibodies. Br J Haematol. 1990;74:1-9.
27. Tripplett DA, Brandt JT, Kaczor D, Schaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol. 1983;79:678-682.
28. Harris EN, Gharavi AE, Tincani A, Chan JK, Englert H, Mantelli P, Allegro F, Balestrieri G, Hughes GR. Affinity-purified anti-cardiolipin and anti-DNA antibodies. J Clin Lab Immunol. 1985;43:746-748.
29. Pierangeli SS, Harris EN, Gharavi AE, Goldsmith G, Branch DW, Dean WL. Are immunoglobulins with lupus anticoagulant activity specific for phospholipids? Br J Haematol. 1993;85:124-132.
30. Harris EN, Pierangeli SS, Birch DJ. Report of an anticardiolipin wet workshop: Vth International Symposium on Antiphospholipid Antibodies. Am J Clin Pathol. 1994;101:616-624.
31. Harris EN, Pierangeli SS, Gharavi AE. Diagnosis of antiphospholipid syndrome: a proposal for use of laboratory tests. Lupus. 1998;7(suppl 2):S144-S148.
32. Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioral patterns. Br J Haematol. 1978;40: 143-150.
33. Reinhold R, Fine J. A technique for quantitative measurement of endotoxin in human plasma. Proc Soc Exp Biol Med. 1971;137:334-337.
34. Colden-Stanfield M, Radcliffe D, Cramer EB, Gallin EK. Characterization of influenza-virus-induced leukocyte adherence to human umbilical vein endothelial cell monolayers. J Immunol. 1993;151: 310-321.
35. Colden-Stanfield M, Kalinich JF, Gallin EK. Ionizing radiation increases endothelial and epithelial cell production of influenza virus and leukocyte adherence. J Immunol. 1994;153:5222-5229.
36. Peter FW, Schuschke DA, Wang WZ, Anderson GH, Franken RJPM, Gu J, Pierangeli SS, Barker JH. Do leukocytes contribute to impaired microvascular tissue perfusion after arterial repair? Microsurgery. 1998;18: 23-28.
37. 2GP1) alone. Lupus. 1998;7:341-346.
38. Pierangeli SS, Harris EN. Antiphospholipid antibodies in an in vivo thrombosis model in mice. Lupus. 1994;3:247-251.
39. Del Papa N, Guidali L, Sala A, Buccellati C, Khamashta MA, Ichikawa K, Koike T, Balestrieri G, Tincani A, Hughes GRV, Meroni PL. Endothelial cells as target for antiphospholipid antibodies. Arthritis Rheum. 1997;40:551-561.
40. McCrae KR, DeMichele A, Samuels P, Roth D, Kuo A, Meng Q-H, Rauch J, Cines D. Detection of endothelial-cell reactive immunoglobulin in patients with anti-phospholipid antibodies. Br J Haematol. 1991;79: 595-605.
41. Lai CJ, Rauch J, Cho CS, Zhao Y, Chukwaocha RU, Chen PP. Immunological and molecular analysis of three monoclonal lupus anticoagulant antibodies from a patient with systemic lupus erythematosus. J Autoimmun. 1998;11:39-51.
42. Bachman RL, Silverstein RL. Hypercoagulable states. Ann Intern Med. 1993;119:819-827.
43. Nachman RL, Hajjar KA, Silverstein RL, Dinarello C. IL-1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med. 1986;163:1595-1600.
44. Ferro D, Pittoni V, Quintarelli C, Basili S, Saliola M, Caroselli C, Valesini G, Violi F. Coexistence of antiphospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with on-going prothrombotic state. Thromb Haemost. 1997;75(suppl):359.
45. Martini F, Farsi A, Gori AM, Boddi M, Fedi S, Domeneghetti MP, Passaleva A, Prisco D, Abbate R. Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus. Lupus. 1996;5:206-211.
46. 2-glycoprotcin 1 antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation. 1998;97:900-906.